Luye Pharma Group Ltd (LUP) - Total Liabilities

Latest as of December 2025: €14.47 Billion EUR ≈ $16.91 Billion USD

Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has total liabilities worth €14.47 Billion EUR (≈ $16.91 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Luye Pharma Group Ltd (LUP) net asset momentum to track the company's year-over-year net asset growth rate.

Luye Pharma Group Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Luye Pharma Group Ltd's total liabilities have evolved over time, based on quarterly financial data. See LUP FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Luye Pharma Group Ltd Competitors by Total Liabilities

The table below lists competitors of Luye Pharma Group Ltd ranked by their total liabilities.

Company Country Total Liabilities
ARIZONA SONORAN COPPER
F:H6F
Germany €122.14 Million
ZEAL Network SE
XETRA:TIMA
Germany €212.18 Million
Prosegur Cash S.A
MC:CASH
Spain €2.28 Billion
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
Mexico MX$6.75 Billion
Canaccord Genuity Group Inc
TO:CF
Canada CA$5.50 Billion
Mivtach Shamir
TA:MISH
Israel ILA4.00 Billion
AMC Entertainment Holdings Inc
NYSE:AMC
USA $9.61 Billion
Shenzhen Changhong Tech
SHE:300151
China CN¥1.04 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Luye Pharma Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Luye Pharma Group Ltd (LUP) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.53 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.90 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Luye Pharma Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Luye Pharma Group Ltd (2016–2025)

The table below shows the annual total liabilities of Luye Pharma Group Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 €14.47 Billion
≈ $16.91 Billion
+4.39%
2024-12-31 €13.86 Billion
≈ $16.20 Billion
+15.85%
2023-12-31 €11.96 Billion
≈ $13.99 Billion
-9.43%
2022-12-31 €13.21 Billion
≈ $15.44 Billion
-1.93%
2021-12-31 €13.47 Billion
≈ $15.75 Billion
+7.47%
2020-12-31 €12.53 Billion
≈ $14.65 Billion
+26.05%
2019-12-31 €9.94 Billion
≈ $11.62 Billion
+3.51%
2018-12-31 €9.60 Billion
≈ $11.23 Billion
+148.54%
2017-12-31 €3.86 Billion
≈ $4.52 Billion
+46.17%
2016-12-31 €2.64 Billion
≈ $3.09 Billion
--

About Luye Pharma Group Ltd

F:LUP Germany Drug Manufacturers - Specialty & Generic
Market Cap
$1.05 Billion
€894.77 Million EUR
Market Cap Rank
#8606 Global
#1133 in Germany
Share Price
€0.22
Change (1 day)
+0.00%
52-Week Range
€0.19 - €0.43
All Time High
€0.70
About

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more